Natural Killer Cell Activity Test Helps to Suspect Aggressive Natural Killer Cell Leukemia - Diagnostic Challenge

Int J Med Sci. 2023 Jan 16;20(2):206-210. doi: 10.7150/ijms.77583. eCollection 2023.

Abstract

Aggressive natural killer cell leukemia (ANKL) is a rare disease with an aggressive clinical course. We aimed to assess the clinicopathological characteristics of the difficult to diagnose ANKL. During ten years, nine patients with ANKL were diagnosed. All the patients exhibited aggressive clinical course and underwent the BM study to rule out lymphoma and hemophagocytic lymphohistiocytosis (HLH). BM examination showed varying degrees of infiltration of neoplastic cells, which were mainly positive for CD2, CD56, cytoplasmic CD3 and EBV in situ hybridization. Five BM aspirates showed histiocytic proliferation with active heomphagocytosis. Normal or increased NK cell activity test results were obtained from 3 patients who were available for testing. Four had multiple BM studies until diagnosis. An aggressive clinical course and positive EBV in situ hybridization, often with associated secondary HLH, should raise the suspicion of an ANKL. Conducting additional supplementary tests such as NK cell activity and NK cell proportion would be helpful for the diagnosis of ANKL.

Keywords: Aggressive natural killer cell leukemia; Epstein-Barr virus; Hemophagocytic lymphohistiocytosis; NK cell activity.

MeSH terms

  • Disease Progression
  • Humans
  • Killer Cells, Natural / pathology
  • Leukemia, Large Granular Lymphocytic* / diagnosis
  • Leukemia, Large Granular Lymphocytic* / pathology
  • Lymphoma*